Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival

Inge G.P. Geelen, Noortje Thielen, Jeroen J.W.M. Janssen, Mels Hoogendoorn, Tanja J.A. Roosma, Sten P. Willemsen, Peter J.M. Valk, Otto Visser, Jan J. Cornelissen, and Peter E. Westerweel

Disclosures: IG, NT, MH, TR, SW, PV, OV and JC have nothing to disclose. Support from work outside the submitted work during the 36 months prior to publication was received by JJ (BMS, Novartis, Pfizer, Ariad) and PW (Bayer, BMS, Celgene, Gilead, Novartis, Pfizer, Takeda, TEVA).

Contributions: IG, NT, OV, JJ and PW designed the study; TR, NT, PV, IG and MH carried out data collection; IG and SW performed the statistical analysis; IG, JJ, JC and PW analyzed the data, IG and PW wrote the initial draft of the manuscript. All authors contributed to interpretation of the results and revision of the paper.